Early Tafolecimab Treatment for Heart Attack Patients Receiving Stent Procedures
Tests early tafolecimab, with cholesterol-lowering drugs, in adults with acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Key facts
- Where
- Beijing and Tangshan, ChinaSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06096909, who can take part
Where in China
- Fuwai HospitalBeijing, ChinaTaking people
- Tangshan Central HospitalTangshan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT06096909
- Record updated
- 27 October 2026
- Original description
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.Read full original descriptionShow less
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled Trial
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.
Inclusion: Patients aged 18 to 75 years; clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ; undergoing PCI; baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina.
Exclusion: Previous hemorrhagic cerebrovascular disease history; Intolerance to statins or cholesterol absorption inhibitors; Severe heart failure (Killip III or IV) or cardiogenic shock; poorly controlled hypertension; malignant tumor; Severe hepatic and renal insufficiency (ALT/AST> 3 times upper limit of normal, eGFR<30 ml/kg/1.73m2, or ongoing dialysis) or creatine kinase elevation>5 times upper limit of normal; Uncontrolled or recurrent arrhythmic events; Intolerance to injections; Life expectancy <1 year; poor compliance.